Ozempic
| Chemical Name | semaglutide |
| Dosage Form | Injection (subcutaneous; 2 mg/1.5 mL) |
| Drug Class | Hormones |
| System | Endocrine, Cardiovascular |
| Company | Novo |
| Approval Year | 2017 |
Indication
- To improve glycemic control in adults with type 2 diabetes mellitus.
- To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.